Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ISCOMs vaccine against experimental leishmaniasis

G Papadopoulou1, E Karagouni, E Dotsika

  • 1Hellenic Pasteur Institute, Athens, Greece.

Vaccine
|July 31, 1998
PubMed
Summary

Immunostimulating complexes (ISCOMs) with Leishmania major surface glycoprotein (gp63) protected mice against infection. This vaccine strategy induced a Th1-biased immune response, reducing inflammation and lesions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Growth factors in relation to obesity, food habits, and microbiota among healthy Saudis: preliminary results.

European review for medical and pharmacological sciences·2023
Same author

Chemical and isotopic characterization of the thermal fluids emerging along the North-Northeastern Greece.

Scientific reports·2021
Same author

Isotopic modeling of the sub-cloud evaporation effect in precipitation.

The Science of the total environment·2016
Same author

O-H-C isotope ratio determination in wine in order to be used as a fingerprint of its regional origin.

Food chemistry·2014
Same author

Toll-like receptor 4 promotes control of Leishmania infantum infection through inducement of leishmanicidal activity in host macrophages: role of mitogen activated kinases.

Journal of biological regulators and homeostatic agents·2014
Same author

KPC-producing, multidrug-resistant Klebsiella pneumoniae sequence type 258 as a typical opportunistic pathogen.

Antimicrobial agents and chemotherapy·2013

Area of Science:

  • Immunology
  • Parasitology
  • Vaccine Development

Background:

  • Leishmania major causes cutaneous leishmaniasis.
  • The surface glycoprotein gp63 is a key target for immune responses.
  • Developing effective vaccines against leishmaniasis remains a challenge.

Purpose of the Study:

  • To evaluate the protective efficacy of gp63 incorporated into immunostimulating complexes (gp63-ISCOMs) against Leishmania major infection.
  • To characterize the immune response induced by gp63-ISCOM vaccination.

Main Methods:

  • Balb/c mice were vaccinated intraperitoneally with gp63-ISCOMs.
  • Vaccinated mice were challenged with Leishmania major.
  • Immune responses were assessed by measuring antibody production, T-cell proliferation, cytokine secretion, and delayed type hypersensitivity.

Main Results:

  • Vaccination with gp63-ISCOMs significantly reduced inflammation and lesion development after challenge.
  • A strong IgG2a antibody response was observed in vaccinated mice.
  • Spleen cells from vaccinated mice showed enhanced proliferation and secreted high levels of IL-2, IFN-gamma, and IL-10 upon restimulation.
  • No delayed type hypersensitivity response was detected.

Conclusions:

  • gp63-ISCOMs effectively induce protective immunity against Leishmania major infection in susceptible mice.
  • The vaccination strategy promotes a Th1-biased immune response, crucial for controlling leishmaniasis.
  • gp63-ISCOMs represent a promising vaccine candidate for leishmaniasis.

Related Experiment Videos